Tag: pharmaceutical

  • ‘Developing robust pharmaceutical base vital’

    ‘Developing robust pharmaceutical base vital’

    • CARISCA summit holds
    • By Christiana Ohimai

    Ekiti State Commissioner for Health and Human Services, Dr Oyebanji Filani has underscored the need for the nation to develop a robust pharmaceutical manufacturing base to stimulate growth, and secure access to essential medicines during crises or donor transitions.

    Filani was the keynote speaker at the fifth Centre For Applied Research And Innovation In Supply Chain-Africa (CARISCA) summit which was held in Lagos.

    He spoke on: “Enhancing Quality and Expanding Access: How Pooled Procurement Purchasing by States can strengthen Nigeria’s Healthcare Delivery.”

    “With the right policy incentives, catalytic financing, and regulatory streamlining, local manufacturers can meet a significant share of national demand—reducing our import dependency and strengthening national health security.

    “When the government provides stewardship and the private sector brings execution, the outcomes improve.

    “We must now move from ad-hoc project partnerships to institutionalised, performance-based frameworks—backed by legislation, coherent policy, and enforceable governance structures.

    “The growth in Drug Management Agencies (DMAs) underscores this potential: from just six active DMAs in 2021, the number increased to 19 by 2023, and today, 26 states out of 37 now have operational DMAs available for strategic partnerships with pharmaceutical companies,” he said.

    Pioneer Dean  LASU School of Transport and Logistics, Prof. Samuel Gbadebo Odewunmi noted that weak logistics infrastructure is a barrier  to functional and sustainable supply chain delivery in Nigeria and Africa.

    According to him, border inefficiency, warehousing, corruption,among others, also affect a reliable supply chain system.

    Prof Adegoke Òkè of the Arizona State University, USA, said the summit  was a platform for the town and gown to find ways to sustainable progress on supply chain and logistics.

    “Supply chain, I know many people heard about supply chain during COVID, but supply chain has always been there,” he said.

    Read Also: NAFDAC confiscates 88,560 litres of bomb making acids in Kano

    CARISCA Director and a Professor of International Marketing and Strategy at the Kwame Nkrumah University of Science and Technology,Ghana, Prof. Nathaniel Boso said since the summit had never been held outside of Ghana, Nigeria being the largest economy in Africa was considered.

    “And so, we thought of Nigeria, being the largest economy in Africa, and the economy also with a high degree of diversity of people, we decided to come here this year to have the summit.

    “We are doing a project here on how to make health supplies more visible such that every point that a pharmaceutical product travels in a health supply chain system, we are able to track it such that if the government of Nigeria orders farmers’ vaccines that are supposed to be supplied to health units across the country, we can see exactly where those health supplies are and in what quantity,” he said.

  • Exit of multinational pharmaceutical companies: An imperative for developing local production capacity

    Exit of multinational pharmaceutical companies: An imperative for developing local production capacity

    By Emmanuel Afunwa

    Significance of multinational pharmaceutical companies

    In the last quarter of 2023 two Multinational Pharmaceutical Companies, GSK and Sanofi, announced they were leaving the Nigerian market and were changing their business model in the country to be handled by a third party to sell their brands. This means they will not be directly involved in the marketing and promotion of their brands in Nigeria henceforth. In the wake of these announcements Procter and Gamble, another pharmaceutical and consumer goods producer also announced it is exiting the Nigerian market. These pronouncements have left many stakeholders in the pharmaceutical industry befuddled considering the roles multinational companies play in local economies in Africa and particularly in Nigeria. Many households rely on products from these companies to meet their health care needs daily and the fear is that these exits may cause disruptions in the steady supply of essential medicinal products which may lead to scarcity and increased prices. As troubling as this may be, it points to the need for us as a country to consider how to strengthen our capacity for local production of pharmaceutical products to ensure our medicines security as a country.

    Reasons for exit of pharmaceutical multinationals

     The multinational companies have cited difficulty in getting foreign currencies, poor power supply, congestion at the ports, multiple taxations, regulatory challenges, complex bureaucracies and dwindling profitability as some of the reasons for leaving the country. The Pharmaceutical giants are changing their models of doing business in Nigeria by appointing local vendors to ensure the availability of their products in the country. They claim that with the existing structure their business they were not profitable which necessitated their exit but it is instructive that this is not peculiar with Nigeria as reports also show they are exiting other African economies which they deemed as unprofitable just like in Nigeria.

    Impact of exit on local economies

     The exit of the multinational pharmaceutical companies will have a huge impact on the local economy. Firstly, there is bound to be job losses which will affect many families and their dependents. Also, shelves of retail pharmacies are already facing scarcity of popular brands of these companies like GSK’s Ventolin inhalers, Augmentin tablets and syrups which in some cases have risen over 100% above their normal prices. Given the fact that many Nigerians buy their medicines out-of-pocket without any support of healthcare financing to cushion the cost of their medicines may lead to poor health outcomes with many patients on medications not being able to afford the cost of their medicines. This may result in those medicines becoming accessible only to wealthy Nigerians who can afford them and unavailable to those who cannot.

     This creates some level of health inequity by design where healthcare is available to the wealthy and unavailable to some others. This defeats the essence of healthcare which should be a fundamental right and accessible to all patients. The scarcity of these medicines may also lead to patients travelling longer distances to buy their medicines which may result in increased indirect healthcare costs like those spent on transportation, especially with the attendant fuel hike in the country.

     For those who have chronic illnesses and are on long-term medications the cost of these medicines may become prohibitive leading to poor health outcomes due to poor adherence to their medicines because of cost.

    Importance of local production

     This exit may be painful but could be seen as a blessing in disguise. It might as well be pointing Nigeria towards a direction of opportunity which is to begin investing massively in local pharmaceutical production to meet its local needs for essential medicines. With the growing population, the attendant needs for essential medicines, closeness to growing neighbouring countries and with over 70% of our local pharmaceutical needs being presently imported there is a huge gap to be filled by embarking on local production of pharmaceuticals in Nigeria. Besides, as a signatory to the Universal Healthcare Coverage (UHC) nothing can be achieved with our current healthcare model without essential medicines to meet the medication needs of the citizens. 

    This approach will ensure safe, effective and affordable medicines are accessible to Nigerians and set us up on the path to medicine security as a nation. With the position of Nigerian in the West African sub-region and the yawning gap for medicines in those countries and opportunity for export will be created. This can set us the path of moving from consumption to production and increased foreign earnings to grow our economy. Borrowing from models adopted by India and China, who have become the global pharmacies where almost every country patronise for their medicines began by becoming intentional with their objective to become self-sufficient with their local drugs production and started exports thereafter. This is the path Nigeria needs to tow for it to meet its local drugs needs and then expand to exports even if it will begin with just the African markets.

    Overcoming inherent challenges

     For Nigeria to set out on this path it needs to fix its petrochemicals and power industries. With the current situation of these two industries, Nigeria will remain a sleeping giant. If the petrochemicals industry and the power sector are revamped there is bound to be an influx of investors who will build the needed infrastructure and modern technology that set the country on the path of production instead of consumption which is the level the country is for now.

    Read Also: Exit of multinational pharmaceutical firms to raise Nigeria’s import bill

     With a population of over 200 million people, the market is here but with a low production capacity, the economy is below what it should be. With adequate investments in terms of infrastructure with modern technology and necessary regulatory reforms there is bound to be growth in the pharmaceutical industry.

    Promoting sustainable solutions: Public-Private Partnerships and capacity building initiatives

     With insights from India’s imports of pharmaceuticals into Nigeria in the business year 2021-2022 is close to $ 600 million there is a need to tap into opportunities inherent in the pharmaceutical industry and become another key player in the sector.

     The Nigerian government should make the environment conducive to all stakeholders for ease of investment by reforming the regulatory framework, creating production incentive schemes, bulk industrial and production drug parks and special loan schemes for pharmaceutical production.

    It could also intervene by funding pharmaceutical research and development, providing financial support for seminars, training, conferences and workshops on pharmaceutical technology upgrades and knowledge transfer to meet WHO-GMP standards, reducing pharma registration red tapes, public-private partnerships are ways the government can encourage small-medium scale players into pharmaceutical production to up their game to scale up their businesses to meet global standards and boost their production capacity initiatives towards achieving the target goals of meeting out local drug needs which is essential for sustainable health security of the country.

    Afunwa, a phamarcist and pharmaceutical policy analyst, wrote via emmafunwa1@gmail.com

  • Bank recapitalisation will help pharmaceutical businesses, says phamacist

    Bank recapitalisation will help pharmaceutical businesses, says phamacist

    Central Bank’s recapitalisation of banks will pave the way for stronger banks to support pharmaceutical businesses and enhance drug security, Chief Executive Officer of St. Rachel’s, Akinjide Adeosun has said.

    Adeosun’s spoke at a media dialogue  in Lagos to mark the sixth anniversary of St. Rachel’s Pharmaceutical Company.

    The event brought together industry leaders and stakeholders to discuss strategies in overcoming obstacles and revitalising manufacturing.

     Adeosun highlighted importance of banking in bolstering pharmaceutical industry, in ensuring stability and growth.

    “CBN’s directive to increase capital requirements is a step to strengthen financial sector,” Adeosun said.

    “Bigger, stronger banks will provide financing to pharmaceutical businesses, thereby enhancing drug security.”

    Addressing challenges, Adeosun stressed the need for supportive policies and will to drive genuine growth.

    He emphasised that while the sector faces challenges, finding sustainable solutions remains a priority.

    Read Also: Stanbic IBTC to extend more loans to businesses

    “Bad policies and lack of will have hindered the sector’s growth for too long,” Adeosun noted. “Our discussion today aims to identify solutions that will propel the industry and the economy to new heights.”

    Key industry stakeholders, including Mrs. Chinyere Almona, director general of Lagos Chamber of Commerce and Industry, and Prince Adewale Oladigbolu, national chairman of  Association of Community Pharmacists of Nigeria, echoed Adeosun’s sentiments.

    They stressed importance of creating an enabling environment for manufacturers to thrive.

    On “Manufacturing Renaissance: The Panacea for Drug Security in Nigeria,” Almona stressed the need for government to address structural, fiscal, and systemic challenges hindering manufacturing, particularly pharmaceuticals.

    She listed unfriendly policies, poor power supply, high cost of transportation, insecurity, high cost of borrowing, high taxes, high cost of foreign exchange, high cost of raw materials, import duties, lack of collaboration as some of the challenges.

    Hailing St. Rachel’s for remaining steadfast despite harsh business ecosystem, Almona said government should tackle the problems to enable Nigerians live quality lives.

  • Pate promises to stem rising drug costs, ease pharmaceutical burden

    Pate promises to stem rising drug costs, ease pharmaceutical burden

    In Nigeria where the clamour of daily life often drowns out quieter concerns, a shadow looms large over the horizon of healthcare. It’s a tale not unique to Nigeria but resonates worldwide—a narrative of escalating pharmaceutical costs that threatens the very foundation of accessible healthcare. Amid this backdrop of mounting pressures stands Prof. Muhammad Ali Pate, the Coordinating Minister of Health and Social Welfare. With unwavering determination, he pledges to navigate these turbulent waters, forging partnerships and policies to alleviate the burden on the population. For in a nation where healthcare is not just a luxury but a fundamental right, the stakes couldn’t be higher. “The rising cost of pharmaceuticals is a major issue that bothers not only Nigeria but the world at large,” he said, affirming that healthcare is crucial for all Nigerians.

    In a dimly lit hall adorned with banners bearing the insignias of pharmaceutical giants, Prof. Pate’s voice cut through the murmurs of anticipation like a beacon in the night. Gathered before him were the titans of Nigeria’s pharmaceutical industry, their faces etched with a blend of concern and resolve. It was an evening steeped in purpose, hosted by the very industry players entrusted with supporting the presidential initiative of unlocking the healthcare value chain. Against this backdrop of shared responsibility, Pate’s words reverberated with urgency, echoing the collective call to action that hung heavy in the air.

    “Tinubu administration is focused on what we can do to reduce the burden of high cost of pharmaceuticals on Nigerians especially the poorest and the most vulnerable ones as the health and welfare of all Nigerians is key to us. So, this first consultation with pharmaceutical stakeholders is very important as they are responsible for the research, development, production and distribution of medications. The pharmaceutical local manufacturers will ensure that the industry strives and Nigerians have affordable medicines that can improve the health of the population of this country.”

    Read Also: Dollarisation: EFCC raises 14 task forces, arrests racketeers

    With a solemn nod, Prof. Pate underscored the indomitable spirit of Nigeria, even in the face of daunting challenges. “Boycotting the issues plaguing the pharmaceutical sector is not an option,” his voice rang out, imbued with conviction. Addressing the concerns head-on, he articulated the government’s unwavering commitment to regulating the quality of pharmaceutical products, a vital step in safeguarding the health of every Nigerian. “We’re in this together,” he declared, a rallying cry to ensure that no citizen is left behind in the pursuit of affordable healthcare. Despite the current hardships, Pate exuded a quiet confidence in Nigeria’s resilience, a belief that echoed through the room like a beacon of hope.

    In a passionate plea echoing through the halls of the pharmaceutical symposium, President of the Pharmaceutical Society of Nigeria (PSN), Prof. Cyril Usifoh, laid bare the critical issues plaguing pharmacists and healthcare delivery in the nation. With unwavering resolve, he urged for pharmacists to be recognised as primary healthcare providers, emphasising the pivotal role they play in routine vaccination and the availability of essential drugs in government hospitals. His call for an enriched drug management agency and the promotion of public-private partnerships reverberated, underlining the urgent need for collaboration and teamwork in healthcare. As his words resonated, hope flickered for a brighter future in Nigerian healthcare.

    Dr. Okey Akpa, President of the Federation of Nigeria Pharmaceutical Industry Associations (FeNPIA), echoed a resounding commitment to partner with the present administration in fostering sustainable access to high-quality, safe, effective and affordable medicines, vaccines, and medical devices. This pledge, woven with determination, symbolised the industry’s unwavering dedication to enhancing healthcare delivery across the nation. With collaborative efforts poised to bridge gaps and uplift standards, Akpa’s words illuminated a path toward a future where every Nigerian can access essential healthcare without the burden of exorbitant costs or compromised quality. “We humbly crave your attention and practical actions to the issues raised. Solving these challenges will make the pharmaceutical industry self-sufficient and help it become a net exporter of medicines, vaccines and medical devices to Africa and beyond.  We will continue to work with the help of our regulators, NAFDAC, PCN and other critical MDAs, government agencies and departments such as NIPRD and the Food and Drugs Department within the Ministry of Health under your leadership in achieving the objectives of unlocking the healthcare value chain.”

  • Time to focus on local pharmaceutical development

    Time to focus on local pharmaceutical development

    Sir: The convergence of pharmaceutical industrial development and healthcare improvement is unveiling a mutually beneficial synergy across various African nations, including Nigeria. This virtuous cycle is driven by shared goals between local health system stakeholders and industrialists. As healthcare providers strive to reduce supply shortages and advocate for increased public funding, local industrial players are eyeing expanded markets. This symbiotic relationship envisions a future where health system strengthening and pharmaceutical industrial development go hand in hand.

    A “local health” policy perspective forms the bedrock of this approach. By identifying local health priorities and leveraging existing industrial capacities, this perspective fosters synergies between health system investments and industrial endeavours.

    Geography, specifically the location of pharmaceutical expertise and manufacturing capacity, plays a crucial role in ensuring health security. African governments, along with inter-governmental organizations like the African Union Commission (AUC), the New Partnership for Africa’s Development (NEPAD), and ECOWAS must actively seek ways to enhance their domestic skills and capabilities. Many policymakers view pharmaceutical manufacturing as a focal point for bolstering long-term health security.

    While a significant portion of pharmaceutical manufacturing in Sub-Saharan Africa primarily involves basic formulations using imported Active Pharmaceutical Ingredients (APIs), there are encouraging signs of increasing technological advancements, accompanied by the necessary scientific and technical know-how. Scientists and manufacturers are actively searching for niche areas to initiate API manufacturing. Economies of scale are of paramount importance in API production compared to formulations, making it challenging for smaller-scale producers to compete. Consequently, potential market niches may include the production of low-dose APIs, especially for the African market.

    The motivation to develop national and regional capabilities in Sub-Saharan Africa is particularly pronounced in the context of pandemic medications and vaccines. There’s a prevailing assumption that in a global pandemic, high-income countries prioritize the treatment and protection of their own populations first. Vaccines and immunization programmes are vital components of saving lives and strengthening healthcare systems. However, nearly all vaccines used in Africa are imported.

    Read Also: BREAKING: PEPC affirms Tinubu’s election, dismisses Atiku, Obi, APM’s petitions

    A study by the Vaccine Manufacturing and Procurement in Africa (AVMI/UNIDO/WHO) revealed that 37 African countries procure all their vaccines through UNICEF, with Africa accounting for around 60% of UNICEF’s total vaccine procurement. Notable exceptions include Senegal’s Institut Pasteur Dakar, which produces a WHO-prequalified yellow fever vaccine, and South Africa’s Biovac, a local public-private partnership engaged in late-stage vaccine development and the production of vaccine vials using imported APIs.

    Developing vaccine manufacturing capabilities faces significant challenges due to intense global competition from major producers and extensive pooled purchasing by UNICEF with the support of development aid funding. The GAVI Alliance is the largest funder in this regard, often requiring UNICEF procurement for the vaccines it funds. Nevertheless, the AVMI study underscores health security as the primary reason for exploring the potential for shifting manufacturing capabilities to Africa, followed by addressing specific unmet needs and pandemic preparedness.

    Vaccine production is inherently risky, featuring high barriers to market entry and extended lead times for product development. Nevertheless, the same study suggests that over the next 10 to 20 years, there is potential for local vaccine production, given projected population growth. It recommends the establishment of regional hubs as the most viable strategy, albeit one that requires political and technical support—an area where AVMI actively advocates and provides technological assistance.

    Producing vaccines and biological products represents a significant challenge for local production, necessitating investments ranging from $60 to $100 million to establish a manufacturing facility. However, the benefits, including elevated skill levels and improved medium-term national health security, are substantial. Expanding vaccine manufacturing efforts would build upon existing capabilities in biological product manufacturing and extensive clinical trial experience in countries like South Africa. Initiatives would require technology transfer, potentially through joint ventures, and would also depend on government and philanthropic support.

    While public health’s focus has expanded to encompass social determinants, the role of industrial development in shaping health outcomes can no longer be overlooked. The interplay between pharmaceutical industrialization and healthcare is an essential element of creating robust African health systems. As African nations invest in industrialization, the global health community’s support is invaluable in extracting optimal benefits for public health.

    Nigeria, with its vibrant potential and rich resources, stands at a crossroads of health and industrial growth. By forging stronger linkages between these two agendas, the nation has an opportunity to rewrite its healthcare narrative. This partnership could not only propel Nigeria toward achieving SDG 3 and universal health care but also contribute to its economic development and global standing.

    •Victor Okeke,

    Centre for Social Justice, Abuja.

  • MAN Pharmaceutical Group urges strong partnerships

    For Nigeria to achieve 70 per cent self-sufficiency in domestic pharmaceuticals, there is the need to adopt strong and innovative partnerships with leading lights in the pharmaceutical manufacturing sub-sector.

    The Pharmaceutical Manufacturers Group of the Manufacturers Association of Nigeria (PMG-MAN) canvassed this position at the fourth Nigerian Pharma Manufacturers Expo (NPME) held in Lagos.

    The Group, through its Chairman, Chief Okechukwu Akpa, said the approach remained one of the most sustainable means the government could drive its bid to secure standardised production and access to quality patent medicines.

    He also said deepening relations with critical stakeholders would effectively drive the requisite investment needed to fix problems facing the sector’s growth.

    Akpa said the challenges of long-term financing, procurement preferences, knowledge and technology transfer and tax incentives, among others, should be addressed to stabilise the operating environment for manufacturers, as well as check counterfeiting.

    Akpa, who noted the group’s contributions to national development via enhancement of access to medicines, reiterated the need to protect the sub-sector through policies that prioritises its growth and efficiency.

    He hailed the Executive Order by Vice-President Yemi Osinbajo directing the mandatory patronage of locally-manufactured medicines by government Ministries, Departments and Agencies (MDAs). He, however, said the directive should be backed with implementation.

    “This policy is expected to accelerate growth and development of the local pharmaceutical manufacturing sector. It will in turn assure national medicines’ security, boost self sufficiency in production, stimulate considerable employment in the sector, and increase inflow of Foreign Direct Investment (FDI),” Akpa said.

    He added that it would also facilitate the export of indigeneous medicines to neighbouring countries. “We therefore, look forward to more partnerships and support from critical stakeholders to ensure the industry continues to play its critical national role and reach its full potential”, Akpa said.

    Drug and Research Director, National Agency for Food, Drug Administration and Control (NAFDAC), Dr. Monica Eimunjeze, who represented the Director-General, Mrs. Yetunde Oni, pledged to support the sector with enhanced regulatory functions.

    She praised efforts at positioning the country as the most concentrated pharmaceutical base in West African, noting that it portends immense opportunities for the sector.

    “We have a responsibility to work to sustain good health through access to quality medicines and vaccines for all. The executive order would be considered to consolidate the effort to expand the local base of pharmaceutical products,” Mrs Oni said.

    MAN President Dr. Frank Udemba Jacobs charged the government to address the security of manufacturing investment in the country.

    He said the country needed to ensure that investors were not discouraged by harsh operatimng environment.

    Jacobs, represented by the Chairman, Ikeja branch of MAN, Prince Oba Okojie, noted that the mandate to deliver a sustainable healthcare could be engineered by robust collaboration with government.

  • Pharmaceutical’s expo to attract 200 exhibitors

    The Pharmaceutical Manufacturers Group of the Manufacturers Association of Nigeria (PMG-MAN) has concluded arrangements to hold the Nigeria Pharmaceutical Manufacturers’ Expo (NPME 2017) in Lagos, from August 30 to September 1.

    PMG-MAN is the umbrella body of local manufacturers of medicines and healthcare products in Nigeria. NPME is the biggest international pharma manufacturing exhibition in West and Central Africa.

    According to its organisers, NPME is the definitive pharma event, and this year, delegates are expected from countries across the continent including Ghana, Mali, Chad,Cameroon, Equatorial Guinea, Central African Republic, Senegal and Morocco. Others are The Gambia, Ivory Coast, Niger, Burkina Faso, Algeria, Benin, and South Africa.

    A statement by PMG-MAN’s Executive Secretary, Dr. Obi Peter Adigwe, said the Expo was billed to attract close to 200 exhibiting companies and nearly 10,000 pharma and related sectors’ trade professionals from across the region.

    According to him, this year’s edition with the theme: Increasing Access to Healthcare in Nigeria: Strategic partnerships to achieve Medicines’ security and national self- sufficiency, is expected to surpass all stakeholders’ expectations.

    Adigwe said this was due to PMG-MAN’s robust and comprehensive advocacy, which has resulted in significant advances in the pharma manufacturing policy landscape in Nigeria as well as on the continent.

    Recently, Vice President Yemi Osinbajo issued an Executive Order on support for local content in public procurement, directing the mandatory patronage of locally manufactured medicines by all Ministries,Departments and Agencies (MDAs).

    Operators say that this policy is expected to accelerate growth and development of the local pharmaceutical manufacturing sector, which will in turn assure national medicines’ security as well as boost self sufficiency in the production of medicines.

    Other positive outcomes associated with these policies include the stimulation of considerable employment in the sector and their capacity to also lead to increased inflow of Foreign Direct Investment (FDI) as well as facilitate the export of Nigerian medicines to neighbouring countries.

    To build on this, the President, West African Pharmaceutical ManufacturersAssociation (WAPMA)/PMG-MAN Chairman, Dr. S. Okey Akpa, during his presentation to the ECOWAS Health Ministers’ Assembly, urged member nations, as well as development partners to support the on-going collaborative efforts to exponentially increase manufacturers’ capacity on the continent.

    This, he argued, was the most sustainable manner to guarantee access to high quality, affordable medicines within the region.

    Another recent development that demonstrates the significant improvement in local pharma manufacturing is the Public-Private Partnership (PPP) signed by the Federal Government with a local firm to produce vaccines in Nigeria.

    While signing the agreement on behalf of the government, Minister of Health, Professor Isaac Adewole, stated that the need to ensure medicines’ security for the nation was a key factor that underpinned the partnership.

    Adigwe, however, said that these policy reforms represent only a fraction of the strategic engagement roadmap developed and initiated by the group to foster a favourable policy environment for local manufacturers.

    He added that this year’s theme was carefully chosen to ensure the timely involvement of all relevant stakeholders in an industry he described as “The jewel of the nation in terms of criticality and potential profitability.”

    Adigwe further indicated that favourable government policies together with the right local and international partners were key factors that could bring Nigeria’s pharma manufacturing industry within a stone’s throw of the Indian model where pharma manufacturing has become a major contributor to India’s $10 trillion economy.

    NPME traditionally showcases a wide range of equipments and input, which cover the entire industry, including allied industries such as food, nutrition, cosmetics and others.  Investors, pharma processing machineries and service providers from a number of countries have already indicated their participation in this year’s NPME.

    Additionally, pharma, healthcare, veterinary, food and beverage, and cosmetic finished products manufactured by local manufacturing companies in Nigeria will be on exhibition at the Expo.

  • Matters pharmaceutical

    Matters pharmaceutical

    As you inch toward the proverbial three score and ten years, you begin to pay closer attention to                    the prescription and off-the counter drugs that have become a part of your daily regimen, particularly    their advertised side effects.

    When the drug comes packaged with the relevant literature in several languages that usually include English, you get to know the possible side effects and to decide whether taking the drug is worth the risks. More on this point later.

    But in Nigeria, drugs often come packaged with instructions in every language except English –French, German, Chinese, Greek, Spanish, Italian, Arabic, Turkish, Serbo-Croat, Korean, Sanskrit, and what have you.  The friendly neighbourhood pharmacist who may have recommended the drug can tell you the dosage, but that is about all the help he or she can render.

    Do something about this, NAFDAC.  In the interest of public health and safety, insist that English must   be one of the languages in which instructions and information on drug imports are written. Allow several months for compliance. Thereafter, punish those in default.

    Trifling as that task might seem compared to the urgent challenge of keeping out of circulation fake, expired and under-performing drugs comprising 70 percent of the market, according to informed sources, it would be a significant step forward.

    Even when all regulations are in place and are duly enforced, you still have to decide whether the drug  is worth the risk.  This is because many the drugs usually prescribed for the afflictions of persons in this age group often have possible side effects that may be even more alarming than the affliction itself.

    Consider, first, a common prescription drug for treating high blood pressure.

    Ordinary side effects include dehydration, which may result in confusion, fast or irregular heartbeat, severe dizziness, or seizures. More serious side effects include non-stop nausea, abdominal pain, yellowing skin, fever, chills, signs of kidney problems, pain in the joints, persistent sore throat, and easy bleeding.

    Consider next the medication for a condition that causes blotches on the skin, discolours the nails, and makes it difficult to use fingers and joints for common, everyday tasks. Side effects include, but are not limited to, feeling faint, swelling in the face, lips, mouth, tongue or throat, trouble breathing or throat tightness, and skin rash.

    Consider as well a prescription drug used in the treatment of various kinds of arthritis.  Possible side effects include tuberculosis and infections caused by viruses or fungi, muscle aches, numbness, problems with vision, weakness in arms and legs, decrease  in blood cells that help fight infectious diseases or stop bleeding, heart failure, liver failure, and cancer.

    Consider, finally, prescription drugs that have suicidal thinking as a side effect.  One drug used in the treatment of asthma belongs in that category.  So does another, used to help adults quit smoking.

    The literature on all of them adds helpfully that what you are reading is only a summary of possible side effects and that you should consult your doctor or pharmacist if you notice others not listed.

    The consolation in all this is that the side effects were for the most part observed in an insignificant number of clinical trials.  Still, a chance is a chance.   One chance in a googol (the figure 1 followed by 100 zeros) might seem comfortingly nebulous, but it is a chance nevertheless.

    The hope must be that the time never comes when a patient faces the stark and urgent choice of continuing to live with a disabling condition or embarking on a cure that may be worse than the disease.

    Re:  With March on my mind

     

    A grave omission . . .

     

    How could I have omitted Chief ‘Folake “The Lady SAN” Solanke, who turned 85 on March 29, from the “children of March” (the phrase is Niyi Osundare’s) whom I sketched last week?

    Chief Solanke is a towering public figure in Nigeria, widely admired for her formidable forensic skills, her distinguished public service, her compelling presence, her poised, regal bearing, her impeccable grooming, her unfailing graciousness, and, of course, her exquisite tailoring.

    Chief Solanke earned a special BA in Latin and Mathematics from the University of Durham, Newcastle-upon-Tyne, in 1954 and followed it up with a Diploma in Education.  She taught high school Latin and Mathematics before returning to Nigeria. Six years later, she was back in the UK, to study at Grays Inn, London, completing the programme in two years.

    She is a woman of many firsts — first woman to set up her own law firm, first to chair the old Western Nigeria Television Service, first female commissioner in former Western State (she held the portfolio of Establishments and Training), and the first to take Silk.

    It was my fortune to chaperon her when she came to Lagos with her husband, the distinguished surgeon, Professor Toriola Solanke, to chair the 1991 Guardian Lecture presented by Ali Mazrui, the multiperspectival scholar of global renown, until his death in 2014 the Albert Schweitzer Professor in the Humanities at the Centre for Global Cultural Studies, University of Binghamton, Binghamton, in upstate New York.

    She presided over the proceedings with grace and finesse, but with firmness when the situation warranted it.  Since then she and Professor Toriola, unfortunately no longer with us, always received  me with their accustomed warmth and graciousness whenever our paths crossed.

    When Chief Solanke was elected first African president of Zonta International, a global service organisation devoted to advancing the status of women, I wrote to congratulate her on the distinction.

    A week later, my letter came back, with a handwritten note from Chief Solanke thanking me ever so graciously for the spirit behind it but pointing out that what it said was clearly not what I meant, and would I kindly withdraw and replace it with another that reflected what I had meant to say?

    I was shattered.

    “The distinction could have gone to a worthier person,” the letter said in cold print.

    In my handwritten draft, the particular sentence read “The distinction could not have gone to a worthier person.”  My secretary had in an uncharacteristic lapse omitted the critical word “not” and inadvertently turned a congratulatory message into a gross libel.  And I had signed off on the typescript without reviewing it.

    The lesson lives with me to this day.

     

    . . . And a correspondent remembers

     

    Your article “With March on my mind” ignored a particular feminine personality Mariam Abacha with whom I share the March 4 birthday.  She will be remembered as a lady to whom Gen Oladipo Diya carried a big greeting card in one of the intriguing Aso Rock days of the Abacha years.

    One of my two daughters turned to me and said, “Dad, while you and others in Ogun State shivered under Diya, Mariam got him to kneel down in presenting the big card.”

    My other daughter countered, “She must be representing all those born on March 4.”

    Lóbátán!

    That was my consolation. Mariam Abacha turned 70 this year. We share the same day and year of birth. How times fly and change.

    Thanks for the article.

     

     

  • Governor okays pharmaceutical plant for Bayelsa

    Bayelsa State Governor Seriake Dickson has said establishment of a pharmaceutical plant by Enbay Pharmaceutical Industries Ltd, in partnership with foreign companies, will aid industrialisation.

    Deputy Governor Gboribiogha John Jonah spoke on behalf of the governor when the firm’s Managing Director, Mr. Eneye Oweifie, visited the Government House in Yenagoa.

    He said the kind gesture, which was first of its kind, would complement government’s efforts in job creation.

    The governor said he dreamt of such development-oriented projects for a long time, adding that the government would ensure the plant, which was the first to be built at the Bayelsa Industrial Park, began operation as soon as possible.

    Trade, Industry and Investment Commissioner Kemela Okara said the plant, which would be sited at the industrial park at Gbarantoru, Bayelsa State, was a joint venture programme between Bayelsa State Development Investment Corporation and the pharmaceutical company.

    Oweifie said his company and other partners were putting finishing touches towards the take-off of the plant.

    He said his company was partnering pharmaceutical companies from the United Kingdom, Germany and Austria, stressing that the building of the plant would boost employment opportunities.

  • ‘Managing a pharmaceutical company is no tea party’

    ‘Managing a pharmaceutical company is no tea party’

    Olakunle Ekundayo, a seasoned pharmacist is Managing Director/Chief Executive, Drugfield Pharmaceutical Limited. In this interview with Daniel Adeleye he speaks on the challenges and prospects of running a pharmaceutical company among other issues. Excerpts:

    As one of the leading organisations in the health sub-sector, what stands you out from your competitors?

    We’re one of the leading drugs manufacturers in Nigeria no doubt about that. I will say what gives us that status is the different dosage forms that we manufactured which many companies don’t. What I mean by dosage forms are tablets, capsules, syrup, suspensions, ointment, infusions, that is large volume injections, which we call drips. So if you look at the activities that we’re engaged in, we’re one of the leading, if not the most diverse pharmaceuticals manufacturer in Nigeria, and that has kept us in the lead. Some of those products like eye drops, injections, both small and large volume, are high technology products that not many may want to dabble into without adequate facilities, So that one has made us to maintain the lead.

    We constantly and regularly upgrade our facilities to keep abreast of modern trends and regulatory demands in the industry. These are in turn matched by qualified human capital with proven track records of work experience in their professional fields of calling such as manufacturing, quality assurance, sales and marketing, regulatory, regulatory, research and development, finance/accounts including human resources and administration.

    Tell us the challenges facing your kind of business in Nigeria?

    There are so many of them. One of which is weak infrastructure. Every Nigerian, as far as you live in this country, is faced with that. But it’s just that when you’re a manufacturer, the consumption of this infrastructure is high. For instance, if you talk about water, what an average home will consume might be to manage to sink a well for their daily activities. But when you talk about manufacturing of drugs, we use a lot of water of diverse qualities. The least of that is portable water that you treat with chemicals to make suitable for human consumption. But when it comes to using this water to manufacture drugs, you step up the quality to produce purified water. Now when you want to make injections or eye drops, you step up the quality to the highest quality of water in that industry which is water for injection. You have to also have distillation system, a system that guarantees the quality of the water is free to make products that you’ll inject directly into the blood stream of human beings. I just talked about water, what about electricity? For the past three years now, we’ve been running on generators. And you can imagine how much we’ll be spending daily, weekly and monthly on fueling and maintenance. It’s huge! Talk about road, we have to use our vehicles; we have to use our own transportation, because we can’t rely on contract transporters. We all know what roads are in this part of the world. Now you need funds to run manufacturing company. We know how costly it is in this part of the world to access funds, with a very high interest rate to build a manufacturing company. There are other problems, the latest of which is access to foreign exchange, which has made the manufacturing sector totally unattractive, because we import 98% of what we need to produce drugs in this part of the world. When it comes to producing drugs, it’s only water that we don’t import in Nigeria. So you can imagine how difficult it could be when there is a problem to access foreign exchange. That is the dilemma which we have found ourselves. Recently, government came up with what they have been announcing as flexible window of foreign exchange, the policy that would make the situation worse. As far as the policy is concerned, it’s not a flexible window, but one window. They devalued naira as much as 40%. If you need N10million to do business before, now you’re going to need N14 or 15million as the case may be. So you can imagine that in an economy where access to fund is difficult, where price of funds is extremely high and you have to now look for funds to procure foreign exchange on forward contract, manufacturing will be extremely difficult. They’re telling you that even at that 280/285 naira to a dollar, by forward contract your suppliers can only get paid after 6o or 90 days. They are telling us that at the end of the 60 or 90 days if naira is selling at 300 to a dollar, you’re going to be asked to pay the difference before your suppliers would get paid. So to me, it’s like government is deliberately defrauding the people. They have devalued the naira and now some of us that placed money with the banks at 197/199 for months will now have to look for over 40% additional and you’re telling us its forward contract. At the end of the contract when the money is due for payment to the beneficiaries, if the exchange rate has gone up, you’re going to be asked for the difference. And if it has gone down, you’ll be paid the difference. But my question is, has anything gone up in Nigeria and ever come down, except it keeps going up? Now government is supposed to be the biggest buyer, the biggest spender but they are the worst when it comes to pay for what they buy from you. I don’t understand the evil spirit that is operating in this country that government will buy your products and they will not pay you for three years. We supplied drugs worth over N83million to the Federal Ministry of Health and they told us that the emergency flood funds was readily available, and that we would get paid immediately. Since November of 2013, government has not paid us a dime. How do you expect people and businesses to survive with this kind of arrangement? And not only that, you don’t get protection from them (government). They allow importers of finished products to bring in goods from anywhere in the world with zero per cent duty. Whereas indigenous manufacturers pay between five and 20 per cent on what we import to manufacture the same products in Nigeria where we employ Nigerians, we employ capital, we pay tax and all that. The problems manufacturers face here in Nigeria is quite overwhelming. Government needs to look into a lot of things very quickly if they really want the change mantra to make sense to anyone.

    What philosophy drives your processes and operations?

    Our commitment to quality in all ramifications is truly our hallmark. From procurement of materials all through manufacturing to consumption and beyond, adherence to high quality standard without compromise is a culture that has endeared us to the hearts of many. Beyond financial postulations, we place premium on the place of our name, image, products and services with authenticated cutting edge emphasis that makes business a manifestation of integrity, efficacy and trust. In Drugfield Pharmaceuticals Limited, we are committed to the manufacture, and distribution of high quality medicinal products that meet the needs of our customers. This we do by engaging competent personnel, modern technology and high quality materials in a conducive and friendly work environment while adhering strictly to current Good Manufacturing Practices, Applicable laws and Regulatory requirements.

    What has been the toughest business decision you have had to take in your capacity as MD/CEO running of Drugfield Pharmaceuticals Ltd?

    The toughest decision I have made is to remain committed to the well being of Nigerians as a manufacturer of drugs. Because, I tell you, for an ordinary mind, we would have been out of this business many years ago because of these layers of obstacle, but it’s a decision that I made that this is like a divine call for me and I must hold on to it and believe God that whatever I do here, the reward is with Him. Though there would be challenges and obstacles, I only need to continue to fight, pray for the way out and do what I know best to do.

    Tell us about your management style. Are you micro or macro managed?

    Well, I don’t understand what you mean by micro or macro managed, but what I will tell you is that the pharmaceutical manufacturing sector is highly regulated. We have so many government organisations regulating our practices. NAFDAC is there, you can’t manufacture without NAFDAC’s approval of both your facilities and products. The Pharmacists Council of Nigeria is there also, you can’t be a manufacturer of drugs without having their certification. We have external bodies in Nigeria who also regulate some of the aspects of our practices. There is ISO certification which is a quality certification we signed unto. So under these regulations, you cannot micro manage, because there are set standard requirements that they expect you to meet. They’re interested in who does what, and to add to that, the Chlorhexidine gel (a medicine for the treatment and prevention of umbilical cord infections in newborns) that is one of our very important products, for which we are the First Manufacturer is one of the 19 essential life saving commodities of the United Nations. So as a manufacturer of that product, some international organizations are also interested in our quality of manufacturing. So under such atmosphere, you cannot micro manage.

    How do you motivate your staff?

    What motivates me is what drives how I motivate my staff. Because my thought is the seat of my action. So if in my spirit, I have a divine call to manufacture drugs to heal the sick, whatever I do in the course of making this available, my action as I said, I derive from my thought, and my thoughts are derived from divine calling.

    How do you reprimand or caution the erring ones, do you implore carrot and stick approach? 

    For a company of our size, we have what we call applicable laws that guide everyone’s conduct, dos and don’ts. These dos and don’ts also subsist in the law that governs Nigeria as a country because we operate in Nigeria. So we have handbook that states everything that if you violate those laws, the consequence is in there. For instance, if you resume late to duty, fight within the company’s premises, or you’re caught with the company’s product and you cannot show the evidence that such product was given to you by due process, because we have mini clinic and designated authorities where you can go and get drugs if the need arises, if you go against this, the law will be applied. And once in a while we do have people who are greedy and not satisfied with what the company gives them, who violate or go against the rules. But since everyone is made to understand the law by giving a copy to each of them, to read and understand the consequences, they would be made to face the music.

    What makes you tick?

    The only motivation I have is that, I regard what I do as a calling, calling by God and not by man. And that is what motivates me to do what I love to do every day; and see how to survive and navigate the difficult terrain that we are. That is what motivates me.

    It’s been over two decades of Drugfield Pharmaceutical Ltd, and a good story too. But where do you see the organization in another decade?

    If you look at how and where we are coming from we started with just one product, Penicillin Cream Ointment, to treat wounds, and you look at where we are 23years after, we now over the years have grown gradually to make products that you can even inject into the human body, products that you can use to treat eyes. So we see ourselves going beyond just making the products, but making some ingredients that we’ll not have to import. Not only that, the industry all over the world is a very dynamic one that is always changing with modernisation. Good manufacturing practices are always being upgraded, so the company has a clear vision to be relevant at all times. Part of what you must position yourself to do is to upgrade from time to time. And that is what has been happening with some of our key lines. Of course, export is also another area that we’re currently looking into. In another decade, we see the entire sub-region as our market, and gradually we’re doing that now. Already in the African market, we are increasing our operational presence in most countries; we believe that we’ll get there in spite of all hurdles.